Takeda says FDA approves its treatment for colorectal cancer
Pharmaceutical company Takeda 4502, said Wednesday that the U.S. Food and Drug Administration approved Fruzaqla as a treatment for certain patients with colorectal cancer. Fruzaqla, or fruquintinib, an oral targeted therapy, was approved for adults with metastatic colorectal cancer who had…
#fruzaqla